Efficacy and safety of thalidomide in the treatment of adult refractory ulcerative colitis.
SHU Hui-jun
YANG Hong
WANG Zheng
FEI Gui-jun
QIAN Jia-ming
Abstract：Objective To evaluate the efficacy and safety of thalidomide in the treatment of refractory ulcerative colitis (UC). Methods Adult patients with refractory UC and treated with thalidomide from Nov. 2009 to Nov. 2017 were included. Their clinical records were reviewed. Results Among the 11 refractory UC patients, 2 were severely active, 3 were moderately active, 5 were mildly active, and 1 was in remission. After treatment with thalidomide, the clinical remission, effective and ineffective rates were 50. 0％(5/10), 10. 0％(1/10), and 30. 0％(3/10) respectively. One patient had thalidomide stopped because of adverse reactions (ADR). Among the 7 patients in remission,one lost to follow up, 5 out of 6 patients achieved clinical remission could maintain remission during the observation period of 30 to 56 months, and all of them achieved mucosal healing. Eight out of 11 (72. 7％) patients had ADRs, including numbness of hands and feet, conspitation, somnolence, dizziness, rash, liver function abnormity, and sweatiness. Conclution Thalidomide can induce and maintain clinical remission and also achieve mucosal healing in adult refractory UC. However, its ADRs should be closely monitored during treatment.
Keywords：ulcerative colitisthalidomideremission inductionmucosal healingadverse reactions
Publication Date：2018-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 223-226 )